Fatty Liver, Nonalcoholic
Conditions
Brief summary
honey is a natural functional food used in control cardiovascular risk factors but its effect on fatty liver is not investigated
Detailed description
Forty fatty liver (non-alcoholic from) patients with obesity are included to be divided into group 1 who will contain 20 patients who will receive honey intake (orally, as a daily total dose of 2 g/kg, this dose will be divided to three equal subdoses, every dose will be administered before meal), low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks. Group 2 who will contain 20 patients who will receive low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
Interventions
BEHAVIORALhoney intake and lifestyle changes
Twenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive natural unprocessed honey intake (orally, as a daily total dose of 2 g/kg, this dose will be divided to three equal subdoses, every dose will be administered before meal), low calorie diet, and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
BEHAVIORALlifestyle changes
Twenty fatty liver (non-alcoholic from) patients with obesity are included as 20 patients who will receive low calorie diet and treadmill walking (40 minutes per session, three times per week) for 12 weeks.
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
30 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* fatty liver (non alcoholic form) * both sexes included * obese subjects (class I)
Exclusion criteria
* cardiac insult * respiratory insult * renal insult * lower limb insult
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| High density lipoprotein | it will be assessed after 12 weeks | it will be measured in serum |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cholesterol | it will be assessed after 12 weeks | it will be measured in serum |
| low density lipoprotein | it will be assessed after 12 weeks | it will be measured in serum |
| alanine transamianse | it will be assessed after 12 weeks | it will be measured in serum |
| triglycerides | it will be assessed after 12 weeks | it will be measured in serum |
| fasting blood glucose | it will be measured after 12 weeks | it will be measured in serum |
| body mass index | it will be measured after 12 weeks | it will be measured on empty stomach |
| waist circumference | it will be measured after 12 weeks | it will be measured on empty stomach |
| aspartate transamianse | it will be assessed after 12 weeks | it will be measured in serum |
Countries
Egypt
Contacts
Primary ContactAli MA Isamil, Lecturer
Backup ContactAlshaymaa S Abd El-Azeim, Lecturer
Outcome results
None listed